II BIENNAL CONGRESS of the. European Network for the Study of Cholangiocarcinoma (ENS-CCA) Rome Italy

Transcription

1 II BIENNAL CONGRESS of the European Network for the Study of Cholangiocarcinoma (ENS-CCA) Rome Italy June 21 st 22 nd 23 rd

2 II BIENNAL CONGRESS of the European Network for the Study of Cholangiocarcinoma (ENS-CCA) Rome, Italy, June 21 st - 22 nd - 23 rd, 2018 Organized by the European Network for the Study of Cholangiocarcinoma (ENS-CCA) or 2

3 II BIENNAL CONGRESS European Network for the Study of Cholangiocarcinoma (ENS-CCA) Rome SCIENTIFIC ORGANIZING COMMITTEE COURSE DIRECTORS Domenico Alvaro, MD (Sapienza University of Rome, Rome, Italy) Jesús M. Banales, PhD (Biodonostia Institute, Donostia Hospital, San Sebastian, Spain) Antonio Benedetti, MD (Marche Polytechnic University, Ancona, Italy) Eugenio Gaudio, MD (Sapienza University of Rome, Rome, Italy) Marco Marzioni, MD, PhD (Marche Polytechnic University, Ancona, Italy) LOCAL ORGANIZING COMMITTEE Maria Consiglia Bragazzi, MD (Sapienza University of Rome, Rome, Italy) Vincenzo Cardinale, MD (Sapienza University of Rome, Rome, Italy) Guido Carpino, MD (Sapienza University of Rome, Rome, Italy) Daniele Costantini, BSC (Sapienza University of Rome, Rome, Italy) Sabina Di Matteo, BSC (Sapienza University of Rome, Rome, Italy) Antonio Franchitto, MD (Sapienza University of Rome, Rome, Italy) Lorenzo Nevi, BSC (Sapienza University of Rome, Rome, Italy) Paolo Onori, MD (Sapienza University of Rome, Rome, Italy) 3

4 II BIENNAL CONGRESS European Network for the Study of Cholangiocarcinoma (ENS-CCA) SCIENTIFIC INFORMATION Rome Cholangiocarcinoma (CCA) is a heterogeneous group of malignancies that may originate from every portion of the biliary tree. It is the second most common primary liver tumor and the incidence is increasing worldwide. CCA has a very bad prognosis due to its aggressiveness, late diagnosis and treatment refractory nature. In May 2015, the European Network for the Study of Cholangiocarcinoma (ENS-CCA: / was created to promote and boost international research collaborations on the study of CCA at basic, translational and clinical level [Banales JM, et al. Nature Reviewers Gastroenterology & Hepatology 2016]. The network is established by 33 active research groups from 12 European countries, including an International Advisory Board of distinguished collaborators from USA, most EASL Members. A European Registry Data Collection on Cholangiocarcinoma (CCA) was created as one of the first initiative (also supported by EASL). Currently, data from more than 350 patients have been collected and we expect to increase this number to more than 2000 patients in the next two years. A main goal of the registry is to create a virtual biobank of biologic samples (biopsies, serum, etc.) from CCA patients. Apart from the registry a number of collaborative multicenter studies have been planned within the network on different areas of CCA including: Basic Science, Histo-morphology characterization, Molecular profiling, Epidemiology and clinical characterization (including clinical trials) and Early diagnosis biomarkers and tools. 4

5 II BIENNAL CONGRESS European Network for the Study of Cholangiocarcinoma (ENS-CCA) Rome Now we are planning to organize the II Biennal Congress of the network with the following main objectives: - To update all the participants on the progress of the Registry. - To discuss potential improvement of the Registry organization and future developments; - To discuss Registry data so far collected on CCA patients, including classification, morphology, risk factors etc. - To discuss preliminary results and the progress of collaborative studies so far organized; - To propose new multicenter collaborative studies with particular attention to: surveillance of population at risk genetic and epigenetics biomarkers for diagnosis and prognosis new diagnostic tools targeted therapies - To discuss feedback of the application to the European cost-grant - To plan future applications for European funds including Horizon2020 In general, the congress will be organized in 20 min presentations with this scheme: update on the topic and preliminary results (5 min.) proposal of collaborative studies (10 min.) and discussion with the audience (5 min). In addition, 8 original abstracts submitted by young investigators (under 40 years old) will be selected for oral presentation. 5

6 PRELIMINARY PROGRAMME Thursday, June 21 st Registration Welcome from local authorities (Rector, Dean, Chief of Dep.) Introductory remarks Domenico Alvaro (Rome, Italy) Jesús M. Banales (San Sebastian, Spain) Antonio Benedetti (Ancona, Italy) Eugenio Gaudio (Rome, Italy) Marco Marzioni (Ancona, Italy) The European Registry Data Collection on Cholangiocarcinoma: an update Jesús M. Banales (San Sebastian, Spain) The European Histology Registry on Cholangiocarcinoma: an update! Guido Carpino (Rome, Italy) General Discussion Social gathering 6

7 Friday, June 22 nd Genetic and Epigenetic Chairs: Jesper Bøje Andersen (Copenhagen, Denmark) Marcin Krawczyk (Homburg, Germany - Warsaw, Poland) Validation phase of GWAS on CCA: new collaborative project Lewis Roberts (Rochester, MN, USA) Elucidation of epigenetic aberrations in clean histopathological subsets of CCA: comparison to transcriptome and chromatin remodeling alterations, disease causality or marks driving molecular/pathological heterogeneity Jesper Bøje Andersen (Copenhagen, Denmark) Genetics of cholangiocarcinoma in pre-defined subgroups of patients - proposal of a NGS-based study Marcin Krawczyk (Homburg, Germany - Warsaw, Poland) Whole exome sequencing of primary sclerosing cholangitis- associated biliary tract cancers Trine Folseraas (Oslo, Norway) 7

8 Friday, June 22 nd Pathology and Signaling Chairs: Mario Angelico (Rome, Italy) Giovanni Brandi (Bologna, Italy) Diego F. Calvisi (Greifswald, Germany) The role of the melatonin/gnrh axis in cholangiocarcinoma growth Gianfranco Alpini (Temple, TX, USA) Bile acids and sphingolipids in cholangiocarcinoma. Huiping Zhou (Richmond, VA, USA) Anti-Wnt therapies, liver fibrosis, blood bile barrier and Wnt signaling in liver cancers Kari Nejak-Bowen, Satdarshan P. Singh Monga, (Pittsburgh, PA, USA) The role of IL-6 cytokines in CCA development Heike M. Hermanns (Würzburg, Germany) Functional and molecular characterization of prevalently mutated oncogenes in CCA through functional genomics and mouse genetics: the role of KRAS in tumor initiation and maintenance Silvestre Vicent (Pamplona, Spain) Coffee Break (20 min) 8

9 Friday, June 22 nd Tumor/stroma interaction Chairs: Enrico Cortesi (Rome, Italy) Laura Fouassier (Paris, France) Mario Strazzabosco (New Haven, CT, USA) The immunoregulatory role of tumor associated dendritic cells (tadcs) in the development and progression of cholangiocarcinoma Veronika Lukacs-Kornek, Miroslaw Kornek (Homburg, Germany) Targeting tumor-stroma interactions to prevent lymph node metastatisation in CCA Luca Fabris (Padua, Italy), Massimiliano Cadamuro (Milan, Italy), Mario Strazzabosco (New Haven, CT, USA) Cholangiocarcinoma Patient Derived Organoids as a novel tool for personalized medicine and functional tumour characterization Chiara Braconi (London, UK) Development, histopathological characterization, and signaling pathways investigation of novel mouse models of intrahepatic cholangiocarcinoma based on recently identified mutations Diego F. Calvisi (Greifswald, Germany) Matthias Evert (Regensburg, Germany) Light Lunch (80 min) 9

10 Friday, June 22 nd Biomarkers and diagnostic tools (1 st part) Chairs: Adolfo F. Attili (Rome, Italy) José Juan Garcìa Marin (Salamanca, Spain) Joachim C. Mertens (Zurich, Switzerland) Usefulness of plasma membrane transporters as biomarkers and molecular targets in cholangiocarcinoma José Juan Garcìa Marin (Salamanca, Spain) The big myth, liquid biopsy for the identification and differentiation between HCC and CCA, can it be done? Veronika Lukacs-Kornek, Miroslaw Kornek (Homburg, Germany) Development of a blood-based surveillance test for early detection of cholangiocarcinoma in PSC patients Guro Elisabeth Lind (Oslo, Norway) International validation study of a panel of prognostic biomarkers in tumor tissue from CCA patients Jesús M. Banales (San Sebastian, Spain) 10

11 Friday, June 22 nd Biomarkers and diagnostic tools (2 nd part) Chairs: Trine Folseraas (Oslo, Norway) Pietro Invernizzi (Milan, Italy) Silverio Tomao (Rome, Italy) International validation study of new non-invasive protein biomarkers in serum extracellular vesicles of PSC, CCA, HCC patients Jesús M. Banales (San Sebastian, Spain) Asbestos and intrahepatic cholangiocarcinoma: searching for molecular biomarkers of exposure by next generation sequencing Giovanni Brandi (Bologna, Italy) International cholangiocarcinoma imaging registry database and correlation studies with histo-morphology and genomics (radiogenomic) Vincenzo Cardinale, Guido Carpino, Marco Rengo (Rome, Italy) Coffee break (10 min.) 11

12 Friday, June 22 nd Oral communications (for young investigators) Chairs: Gianfranco Alpini (Temple, TX, USA) Massimo Rossi (Rome, Italy) Satdarshan P. Singh Monga (Pittsburgh, PA, USA) Selected abstracts (4 communications) General Meeting of the Members of the ENS-CCA (2 nd part) ENS-CCA and EASL, ongoing initiatives: update Marco Marzioni (Ancona, Italy) Initiatives for the future Jesús M. Banales (San Sebastian, Spain) Chairs: Jesús M. Banales (San Sebastian, Spain) Domenico Alvaro (Rome, Italy) Jesper Bøje Andersen (Copenhagen, Denmark) 12

13 Saturday, June 23 rd Oral communications (for young investigators) Chairs: Antonio Benedetti (Ancona, Italy) Chiara Braconi (London, UK) Gian Luca Grazi (Rome, Italy) Selected abstracts (4 communications) General Meeting of the Members of the ENS-CCA (1 st part) Cost Grant action: update Vincenzo Cardinale (Rome, Italy) Proposals of grant applications Chairs: Domenico Alvaro (Rome, Italy) Jesper Bøje Andersen (Copenhagen, Denmark) Jesús M. Banales (San Sebastian, Spain) NOVEL THERAPIES Chairs: Pasquale Berloco (Rome, Italy) Felice Giuliante (Rome, Italy) Marco Vivarelli (Ancona, Italy) A phase I/ II, open label, multicenter study to assess the efficacy and safety of ABTL0812 in combination with Gemcitabine and Cisplatin in patients with advanced, metastasic, or surgically unresectable cholangiocarcinoma (Ability Pharma) Jesús M. Banales (San Sebastian, Spain) 13

14 Saturday, June 23 rd Percutaneous Hepatic Perfusion vs. Cisplatin/ Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma (Delcath PHP-ICC-203 clinical study) Jesús M. Banales (San Sebastian, Spain) Targeting SUMOylation dependent S100A4 Nuclear Import by Low-Dose Paclitaxel in Patients with Cholangiocarcinoma (CCA) undergoing Surgical Resection and Liver Transplantation Umberto Cillo, Luca Fabris, Maria Guido (Padua, Italy) Blocking cholangiocarcinoma tumor growth, angiogenesis and EMT using antihistamine treatments & inhibiting mast cell migration Heather Francis (Temple, TX, USA) Primary cilia expression in CCA: from prognostic marker to preventive and therapeutic target Sergio Gradilone (Austin, MN, USA) INTERACTIONS BETWEEN IPSCSG AND ENS-CCA Chairs: Jesús M. Banales (San Sebastian, Spain) Tom Hemming Karlsen (Oslo, Norway) CONCLUSIVE REMARKS 14

15 II BIENNAL CONGRESS European Network for the Study of Cholangiocarcinoma (ENS-CCA) Rome GENERAL INFORMATION Congress Venue Sapienza University of Rome Department of Anatomy Via Alfonso Borelli, Rome, Italy Organizing Secretariat Spazio Congressi S.r.l. Via Alfredo Catalani, Rome, Italy Tel.-Fax: Registration Conference Registration is free and reserved up to 150 attendees. Registration includes: Access to scientific sessions Lunch, coffee breaks Attendance Certificate To register please contact the Organizing Secretariat Spazio Congressi Language The official language of the conference is English. Simultaneous translation will not be provided. Discover the city of Rome, Italy City Web Site: Public Transportation: Climate 15

16